Toxicity

Explore how HypoSkin®—a standardized, injectable, and immunocompetent human skin model—provides a translational, animal-free solution for assessing the immunogenicity of therapeutic compounds. From structural stability to real-time immune response profiling, this white paper delivers data-backed insights designed for pharma and biotech teams advancing injectable drug development.

Top-level science through the eyes of an expert.Join us for the next session in Genoskin’s webinar series, where we explore cutting-edge advancements in drug delivery and therapeutic innovation. This session will feature an in-depth presentation on polymer prodrug nanocarriers, showcasing a novel approach to controlled and efficient drug release. Watch the replayThis webinar explores new research on polymer-drug conjugates inRead more

Genoskin at the SOT 64th Annual Meeting and ToxExpoAdvancing non-clinical toxicity assessment with ex vitro human skin and mast cell models We are excited to participate in the SOT 64th Annual Meeting and ToxExpo, taking place from March 16-20, 2025, at the Orange County Convention Center in Orlando, Florida. As one of the most influential events in toxicology, this meetingRead more

From human skin to human data: Advancing immunogenicity testing with human modelsIn a public workshop organized by the FDA-CRCG group, Dr. Nicolas Gaudenzio, CSO of Genoskin, introduced an innovative platform for assessing immune reactions in response to injected substances using human skin explants. His talk, titled "A new in vitro framework for assessing immunogenicity using comprehensive profiling of injectable humanRead more

Scientific posterEvaluation of local inflammatory reactions following subcutaneous injection of a pro-inflammatory cocktail in a fully human ex vivo skin model. Poster IID2018.Subcutaneous (SC) injections can evoke local reactions such as inflammation or necrosis. Preclinical development of SC therapies relies on animal models to characterize these responses, however, translation of these models to the clinic is often limited and no singleRead more

Injection-Site PainWhich factors influence pain upon subcutaneous injection?Biologics such as vaccines, insulin, monoclonal antibodies, etc., that are now widely developed need to be administered parenterally. While the intravenous (IV) route has historically been the most widely used,  the subcutaneous (SC) route is now accepted and presented as safe and effective, whether in the context of chronic disease or in palliativeRead more